



0040-4039(94)E0592-L


## Access to an Optically Pure Key Intermediate of Dihyromevinolin

Shigeru Nagashima, Teruhiko Taishi, and Ken Kanematsu\*

Institute of Synthetic Organic Chemistry, Faculty of Pharmaceutical Sciences,  
Kyushu University 62, Higashi-ku, Fukuoka 812, Japan


**Abstract:** An enantioselective route to the key intermediate of dihyromevinolin is described.

The mevinic acids compactin, mevinolin, and their dihydro-analogues have attracted considerable synthetic attention because of their biological activity as inhibitors of HMG CoA reductase, the rate-limiting enzyme in cholesterologenesis in man. Most plausible and intriguing strategy depends on the coupling of a decaline portion with a  $\delta$ -lactone moiety.<sup>1</sup> Although several approaches have been attempted toward the construction of the decaline system present in mevinic acids, it is considered the intramolecular Diels-Alder (IMDA) reaction to be the most promising alternative. Interestingly, three different enantiomeric routes to the decaline portion have been reported in the literature recently,<sup>2</sup> all of which were achieved by IMDA reaction; Hanessian *et al.*<sup>2a</sup> and Lewis *et al.*<sup>2b</sup> have developed the enantioselective routes to the decaline systems using L-glutamic acid as the starting material, these routes were long and problematic. We report here a new efficient access to an optically pure key intermediate of dihyromevinolin, based on the allenyl ether IMDA strategy.<sup>3</sup>



We prepared the desired substrate **1**,  $[\alpha]_D^{23} +67.1^\circ$  (*c* 1.3,  $\text{CHCl}_3$ )<sup>4</sup> from the readily available (*R*)-5-methyl-2-cyclohexenone<sup>5</sup> in four steps: (1) treatment of the enone, first with vinylmagnesium bromide in THF, then with aqueous  $\text{H}_2\text{SO}_4$ ; (2) oxidation with  $\text{MnO}_2$  in  $\text{CH}_2\text{Cl}_2$ ; (3) reduction with  $\text{LiAlH}_4$  in


tetrahydrofuran; (4) etherfication with propargyl bromide [aq. NaOH-Et<sub>2</sub>O, Bu<sub>4</sub>NI(cat.); 41% overall yield]. When the ether **1** was heated in *t*-BuOH in the presence of *t*-BuOK (excess) for 1 h, the adduct **3** was obtained as the sole product *via* IMDA reaction of the allenyl ether intermediate **2** (Scheme 1). Without purification, the adduct **3** was treated with 5% solution of 10-camphorsulphonic acid (CSA) in methanol gave the methyl acetal **4**, [ $\alpha$ ]<sub>D</sub><sup>23</sup> -52.0° (*c* 2.5, CHCl<sub>3</sub>) in almost quantitative yield from the propargyl ether **1**.



Reagents and conditions ; (a) *t*-BuOK, *t*-BuOH, reflux., 1 h (b) 5% CSA in MeOH, 0 °C, 30 min., 99% yield from **1**.

Scheme 1

Hydroboration-oxidation of the alkene followed by oxidation (79% overall yield from **4**) furnished the *cis*-fused ketone **5**, [ $\alpha$ ]<sub>D</sub><sup>24</sup> -129.1° (*c* 1.2, CHCl<sub>3</sub>) (Scheme 2). The ketone was converted into the enone **6**, [ $\alpha$ ]<sub>D</sub><sup>25</sup> -137.6° (*c* 1.2, CHCl<sub>3</sub>) by Saegusa's method,<sup>6</sup> and stereoselective conjugate methylation was accomplished using lithium dimethyl cuprate to give the product **7**, [ $\alpha$ ]<sub>D</sub><sup>22</sup> -40.1° (*c* 1.0, CHCl<sub>3</sub>) as a



Reagents and conditions ; (a) BH<sub>3</sub>·THF, THF, 0 °C, 20 h; 10% NaOH, 30% H<sub>2</sub>O<sub>2</sub>, 0 °C to room temperature, 2 h (b) PCC, Celite, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 2 h, 79% yield from **4** (c) LDA, THF, -78 °C, 30 min.; TMSCl, -78 °C to room temperature, 2 h (d) Pd(OAc)<sub>2</sub>, MeCN, 35 °C, 4 h, 89% yield from **5** (e) Me<sub>2</sub>CuLi, Et<sub>2</sub>O, 0 °C, 2 h, 96% (f) K<sub>2</sub>CO<sub>3</sub>, MeOH, reflux., 2 h, 92% (g) *p*-TsNHNH<sub>2</sub>, MeOH, reflux., 2 h (h) BuLi, THF, 0 °C, 2 h (i) Jones reagent, acetone, 0 °C, 2 h, 53% from **8**

Scheme 2

single diastereomer with the methyl group in axial position (96% yield). After epimerization of the methylated ketone **7** (92% yield), the resulting *trans*-fused ketone **8**,  $[\alpha]_{\text{D}}^{26} +141.7^{\circ}$  (*c* 1.0,  $\text{CHCl}_3$ ) was converted into the less-substituted olefin by Bamford-Stevens reaction.<sup>7</sup> Finally, oxidation of the methyl acetal with Jones reagent afforded the desired fused tricyclic lactone **9**,  $[\alpha]_{\text{D}}^{25} +121.6^{\circ}$  (*c* 2.0,  $\text{CHCl}_3$ ) in 53% overall yield from the ketone **8**, whose physical properties agreed with those reported by Hanessian.<sup>2a</sup> Since the lactone **9** has previously been converted into dihydromevinolin,<sup>2a</sup> our work reported herein constitutes its formal synthesis.

Thus, we have developed an efficient route to fused lactones *via* an IMDA reaction of allenyl ethers which permitted the preparation of the tricyclic intermediate for the convenient enantioselective synthesis of dihydromevinolin (11 steps in 32% total yield).

## ACKNOWLEDGEMENT

This work was supported in part by the Sasakawa Scientific Research Grant from The Japan Science Society and the Grant-in-Aid for Encouragement of Young Scientists No. 05857249 from the Ministry of Education, Science and Culture, Japanese Government.

## REFERENCES AND NOTES

- (a) Rosen, T.; Heathcock, C. H. *Tetrahedron*, **1986**, *42*, 4909-4951. (b) Mulzer, J.; Altenbach, H.-J.; Braun, M.; Krohn, K.; Reissig, H.-U. *Organic Synthesis Highlights*; VHC: Weinheim, **1991**, pp. 309-322 and references cited therein.
- (a) Hanessian, S.; Roy, P. J.; Petrini, M.; Hodges, P. J.; Fabio, R. D.; Carganico, G. *J. Org. Chem.*, **1990**, *55*, 5766-5777. (b) Narasaka, K.; Saitou, M.; Iwasawa, N. *Tetrahedron: Asymmetry*, **1991**, *2*, 1305-1318. (c) Blackwell, C. M.; Davidson, A. H.; Launchbury, S. B.; Lewis, C. N.; Morrice, E. M.; Reeve, M. M.; Roffey, A. R.; Tipping, A. S.; Todd, R. S. *J. Org. Chem.*, **1992**, *57*, 5596-5606.
- (a) We have already described the enantioselective route to forskolin intermediate by the analogous strategy, see: Nagashima, S.; Kanematsu, K. *Tetrahedron: Asymmetry*, **1990**, *1*, 743-749. (b) Similarly, an enantioselective approach to construction of the tetracyclic ring system leading to 3 $\alpha$ -hydroxy-15-rippertene has recently been reported as the stage for the key IMDA reaction, see: Metz, P.; Bertels, S.; Fröhlich, R. *J. Am. Chem. Soc.*, **1993**, *115*, 12595-12596 and references cited therein.
- All new compounds gave satisfactory analytical and/or spectral data. For example, **1**: <sup>1</sup>H-NMR ( $\text{CDCl}_3$ )  $\delta$  6.36 (dd, *J*=17.5, 10.6 Hz, 1H), 5.73 (bs, 1H), 5.18 (d, *J*=17.5 Hz, 1H), 5.03 (d, *J*=10.6 Hz, 1H), 4.40-4.25 (m, 1H), 4.27 (dd, *J*=15.7, 2.3 Hz, 1H), 4.20 (dd, *J*=15.7, 2.3 Hz, 1H), 2.42 (t, *J*=2.3 Hz, 1H), 2.30-2.25 (m, 1H), 2.22-2.05 (m, 1H), 1.82-1.59 (m, 2H), 1.17 (td, *J*=12.0, 10.0 Hz, 1H), 1.07 (d, *J*=6.3 Hz, 3H); MS *m/z* 176 ( $\text{M}^+$ , 12.3), 120 (45.9), 105 (100); HRMS *m/z* 176.1198 (calcd for  $\text{C}_{12}\text{H}_{16}\text{O}$  176.1200). **4**: <sup>1</sup>H-NMR ( $\text{CDCl}_3$ )  $\delta$  5.54 (m,

1H), 4.74 (d, J=3.6 Hz, 1H), 4.25 (q, J=5.2 Hz, 1H), 3.38 (s, 3H), 2.51 (m, 1H), 2.43-2.36 (m, 1H), 2.30-2.25 (m, 1H), 2.13-1.97 (m, 2H), 1.93-1.49 (m, 6H), 0.97 (d, J=6.9 Hz, 3H); MS m/z 208 (M<sup>+</sup>, 4.9), 176 (85.6), 91 (100); HRMS m/z 208.1462 (calcd for C<sub>13</sub>H<sub>20</sub>O<sub>2</sub> 208.1464). 5 : <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 4.79 (s, 1H), 4.25 (dt, J=10.2, 7.3 Hz, 1H), 3.34 (s, 3H), 2.80 (dt, J=9.2, 7.8 Hz, 1H), 2.65-2.57 (m, 1H), 2.50 (td, J=7.7, 2.9 Hz, 1H), 2.38-2.31 (m, 2H), 2.10-1.77 (m, 3H), 1.64-1.43 (m, 2H), 1.03 (d, J=6.6 Hz, 3H), 1.01-0.87 (m, 1H); MS m/z 224 (M<sup>+</sup>, 5.4), 192 (68.4), 164 (81.0), 122 (100); Anal. Calcd for C<sub>13</sub>H<sub>20</sub>O<sub>3</sub>: C, 69.61; H, 8.99. Found: C, 69.75; H, 8.91. 6 : <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 6.72 (dd, J=10.1, 3.4 Hz, 1H), 6.06 (dd, J=10.1, 2.1 Hz, 1H), 4.88 (s, 1H), 4.21 (ddd, J=11.4, 9.0, 4.7 Hz, 1H), 3.36 (s, 3H), 3.14 (dt, J=8.1, 2.9 Hz, 1H), 3.00 (q, J=8.3 Hz, 1H), 2.56 (ddd, J=8.5, 5.2, 3.4 Hz, 1H), 2.19 (dt, J=12.8, 4.1 Hz, 1H), 1.82 (dt, J=13.4, 5.0 Hz, 1H), 1.72-1.58 (m, 2H), 1.06 (d, J=6.7 Hz, 3H), 0.91 (q, J=11.8 Hz, 1H); HRMS m/z 223.1325 (calcd for C<sub>13</sub>H<sub>19</sub>O<sub>3</sub> 223.1333); Anal. Calcd for C<sub>13</sub>H<sub>19</sub>O<sub>3</sub>: C, 70.24; H, 8.16. Found: C, 70.29; H, 8.14. 7 : <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 4.84 (s, 1H), 4.20 (ddd, J=9.9, 8.7, 4.8 Hz, 1H), 3.37 (s, 3H), 2.93 (q, J=8.7 Hz, 1H), 2.57-2.49 (m, 1H), 2.44-2.37 (m, 1H), 2.12-1.56 (m, 7H), 1.08 (d, J=5.9 Hz, 3H), 1.06 (d, J=6.3 Hz, 3H), 1.09-0.95 (m, 1H); MS m/z 238 (M<sup>+</sup>, 2.2), 206 (50.7), 178 (47.3), 136 (100); Anal. Calcd for C<sub>14</sub>H<sub>22</sub>O<sub>3</sub>: C, 70.55; H, 9.30. Found: C, 70.55; H, 9.34. 8 : <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 4.81 (s, 1H), 4.35 (q, J=5.9 Hz, 1H), 3.39 (s, 3H), 2.57-2.30 (m, 2H), 2.11-1.83 (m, 4H), 1.76-1.62 (m, 2H), 1.55-1.42 (m, 2H), 1.14-0.94 (m, 1H), 1.10 (d, J=5.3 Hz, 3H), 1.03 (d, J=6.6 Hz, 3H); MS m/z 238 (M<sup>+</sup>, 2.1), 206 (96.0), 178 (47.0), 136 (100); Anal. Calcd for C<sub>14</sub>H<sub>22</sub>O<sub>3</sub>: C, 70.55; H, 9.30. Found: C, 70.46; H, 9.27. 9 : <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 5.64 (dt, J=9.5, 2.3 Hz, 1H), 5.56 (dt, J=9.5, 2.4 Hz, 1H), 4.66 (td, J=6.9, 4.3 Hz, 1H), 2.56-2.52 (m, 1H), 2.45 (dd, J=7.3, 3.7 Hz, 1H), 2.01 (ddd, J=13.7, 7.2, 4.1 Hz, 1H), 1.96-1.78 (m, 3H), 1.69-1.48 (m, 3H), 1.24 (d, J=7.3 Hz, 3H), 1.03 (d, J=6.7 Hz, 3H).

5. Oppolzer, W.; Petrzilka, M. *Helv. Chim. Acta*, **1978**, *61*, 2755-2762.
6. Ito, Y.; Hirao, T.; Saegusa, T. *J Org. Chem.*, **1978**, *43*, 1011-1013.
7. Bamford, W. R.; Stevens, T. S. *J. Chem. Soc.*, **1952**, 4735-4740.

(Received in Japan 31 January 1994)